Loxo Oncology Inc (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of the stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $183.50, for a total value of $565,547.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Naarden Jacob Van also recently made the following trade(s):

  • On Wednesday, June 20th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $178.14, for a total value of $549,027.48.
  • On Tuesday, May 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $137.42, for a total value of $423,528.44.
  • On Wednesday, April 25th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $131.23, for a total value of $404,450.86.

Shares of LOXO stock traded up $5.07 during mid-day trading on Wednesday, hitting $181.06. 620,109 shares of the stock were exchanged, compared to its average volume of 472,329. Loxo Oncology Inc has a 52-week low of $69.00 and a 52-week high of $208.95. The firm has a market cap of $5.62 billion, a P/E ratio of -34.02 and a beta of 2.45.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. The company had revenue of $38.43 million during the quarter, compared to analysts’ expectations of $12.72 million. During the same period in the prior year, the business posted ($0.96) earnings per share. research analysts expect that Loxo Oncology Inc will post 0.91 EPS for the current year.

Several equities research analysts have weighed in on the company. BidaskClub raised Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Ifs Securities lowered shares of Loxo Oncology from a “strong-buy” rating to a “market perform” rating in a research note on Monday, June 4th. JMP Securities increased their target price on shares of Loxo Oncology from $182.00 to $221.00 and gave the stock a “buy” rating in a research note on Monday, June 4th. Morgan Stanley increased their target price on shares of Loxo Oncology from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, June 4th. Finally, Citigroup increased their target price on shares of Loxo Oncology to $235.00 and gave the stock a “buy” rating in a research note on Monday, June 4th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $176.40.

A number of institutional investors have recently modified their holdings of the stock. Lord Abbett & CO. LLC lifted its stake in Loxo Oncology by 20.8% in the 1st quarter. Lord Abbett & CO. LLC now owns 666,771 shares of the biopharmaceutical company’s stock valued at $76,926,000 after buying an additional 114,963 shares in the last quarter. Franklin Resources Inc. lifted its stake in Loxo Oncology by 27.3% in the 4th quarter. Franklin Resources Inc. now owns 494,101 shares of the biopharmaceutical company’s stock valued at $41,594,000 after buying an additional 106,001 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in Loxo Oncology by 2.1% in the 1st quarter. Rock Springs Capital Management LP now owns 316,500 shares of the biopharmaceutical company’s stock valued at $36,515,000 after buying an additional 6,500 shares in the last quarter. Opaleye Management Inc. lifted its stake in Loxo Oncology by 1.8% in the 1st quarter. Opaleye Management Inc. now owns 179,400 shares of the biopharmaceutical company’s stock valued at $20,697,000 after buying an additional 3,100 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in Loxo Oncology by 2.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 110,975 shares of the biopharmaceutical company’s stock valued at $12,804,000 after buying an additional 2,960 shares in the last quarter.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.